Alvotech Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $212 million for the first half of 2026, down 31% from $306 million in the same period last year.

Adjusted EBITDA: $46 million, a decrease from $54 million year-over-year.

Gross Margin: 54%, consistent with the prior year.

Q2 Revenue: $106 million, a 39% decline compared to Q2 2025.

Q2 Adjusted EBITDA: $23 million, down 32% year-over-year.

Cash Position: $143 million at the end of June, bolstered by a $165 million equity financing completed in June.

Product Revenue: $106 million in the first half, with five biosimilars contributing to revenue.

2Strategic Updates and Business Highlights

Significant investments were made in manufacturing and quality systems, leading to the resubmission of four biologics license applications (BLAs) to the FDA for AVT05, AVT06, and others.

Manufacturing operations returned to planned levels by the end of Q2, with expectations of strong product availability in Q4.

Alvotech is positioned as a first-mover in the ENTYVIO biosimilar market, with a strong pipeline of over 30 biosimilars in development.

The company is expanding its commercial portfolio and exploring direct commercialization opportunities in the U.S.

3Forward Guidance and Outlook

2026 Revenue Guidance: Reaffirmed at $650 million to $700 million, with adjusted EBITDA expected between $180 million and $220 million.

Anticipation of a strong Q4 driven by improved manufacturing output and product availability.

The company expects to see significant growth in 2027 as manufacturing normalizes and new product launches occur.

4Bad News, Challenges, or Points of Concern

Revenue and EBITDA declines reflect the impact of manufacturing slowdowns due to facility improvements.

The company faces competitive pressures, particularly with ongoing litigation related to patent infringements that could affect the launch of its Simponi biosimilar.

The timing of milestone revenues is uncertain and can be lumpy, which may affect financial predictability.

5Notable Q&A Insights

Management expressed confidence in the U.S. launch timeline for Simponi, contingent on resolving ongoing litigation, with expectations for a decision in Q4.

The company is optimistic about its position in the market despite competitive pressures from other biosimilars, particularly with AVT05.

Discussions are ongoing regarding potential licensing agreements for unpartnered assets in the U.S. market.

The collaboration with Fujifilm is progressing well, with product expected to come from this partnership in late 2027.

Provisions taken in the quarter were related to commercial and contractual matters, but details remain confidential due to their sensitive nature. Overall, Alvotech is navigating a challenging environment with declines in revenue but is positioning itself for future growth through strategic investments and a robust pipeline.